Danish biotech Zealand Pharma is targeting the "next generation" of weight loss drugs as competitors pile into a market ...

There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.

The $200B GLP-1 market is set to expand with 16 new obesity drugs launching by 2029, challenging Novo Nordisk and Eli Lilly's ...

A group representing makers of compounded drugs sued FDA over its decision to call an end to the shortage of Lilly's (LLY) ...

The FDA, in a stark reversal, on Friday said it would reconsider its decision to remove Eli Lilly’s tirzepatide from its ...

Eli Lilly is considering testing its blockbuster weight-loss drugs in people who are not overweight but are at risk of weight ...

Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, ...

Eli Lilly And Co. (NYSE:LLY) is ramping up its legal campaign against the compounding companies temporarily allowed to make ...

Eli Lilly (NYSE:LLY) has expanded its ongoing collaboration with Swiss biotech KeyBioscience in a bid to obtain global rights ...

Eli Lilly said Wednesday it will invest $4.5 billion to build an advanced pharmaceutical drug manufacturing and development ...

Hims & Hers Health shares tumbled Thursday after the Food and Drug Administration said Eli Lilly's popular weight-loss drugs ...